PMV Pharmaceuticals, Inc.
PMVP evidence brief
What we can confirm
- Market Cap:
- $71.1M
What it means
What to watch
Prepared research question
What matters most for PMVP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMVP
PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53, with its lead candidate rezatapopt in Phase 2 for p53 Y220C-mutant solid tumors and an NDA submission planned for Q1 2027 [sec_mda · as of 2026-08-14].
Key risk: Cash runway limited
Market Cap
$71.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for PMV Pharmaceuticals, Inc..
PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53, with its lead candidate rezatapopt in Phase 2 for p53 Y220C-mutant solid tumors and an NDA submission planned for Q1 2027 [sec_mda · as of 2026-08-14].
- Lead candidate rezatapopt is a small molecule structural corrector of mutant p53 Y220C protein, currently in Phase 2 [pipeline].
- Enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE trial for platinum-resistant/refractory ovarian cancer completed [news · 2026-08-14].
- NDA submission for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027 [news · 2026-08-14].
- Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026, providing expected cash runway through Q2 2027 [news · 2026-08-14].
- FDA Fast Track designation granted in October 2020 for rezatapopt for p53 Y220C-mutant solid tumors [sec_mda · as of 2026-08-14].
What works
- Rezatapopt has FDA Fast Track designation and orphan drug designation (ODD) for TP53 Y220C-positive ovarian cancer, supporting an accelerated approval pathway [sec_mda · as of 2026-08-14].
- The company has a clear near-term regulatory milestone with an NDA submission planned for Q1 2027 [news · 2026-08-14].
- PMV Pharma raised $50.8 million in September 2026 to fund its cancer drug development [news · 2026-09-01].
- A clinical collaboration with Merck to evaluate rezatapopt in combination with KEYTRUDA is in place [pipeline].
What to weigh
- The company continues to incur significant research and development and general and administrative expenses, with net income of -$18.1M as of 2026-06-30 [sec].
- Cash runway is only through Q2 2027, and operating expenses are expected to increase significantly as the company advances toward regulatory approval and commercialization [sec_mda · as of 2026-08-14].
- The company has no approved products and is entirely dependent on the success of rezatapopt [sec_mda · as of 2026-08-14].
- Past operating results are not necessarily indicative of future results, and the company faces the inherent risks of clinical development and regulatory approval [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Rezatapopt is a small molecule structural corrector of mutant p53 Y220C protein.
“Small molecule structural corrector of mutant p53 Y220C protein”
Pipeline
Enrollment for primary analysis in Phase 2 monotherapy portion of PYNNACLE completed.
“Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed”
News · August 14, 2026
NDA submission for accelerated approval planned for Q1 2027.
“Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027”
News · August 14, 2026
Cash position as of June 30, 2026.
“Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026”
News · August 14, 2026
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash runway only through Q2 2027; expenses expected to rise significantly [sec_mda · as of 2026-08-14].
- Single-product dependency — Company has no approved products; entirely dependent on rezatapopt success [sec_mda · as of 2026-08-14].
- Clinical and regulatory risk — Phase 2 data may not support accelerated approval; past results not indicative of future [sec_mda · as of 2026-08-14].
What to watch
- NDA submission for rezatapopt in Q1 2027 and FDA acceptance decision [news · 2026-08-14].
- Interim Phase 2 data from PYNNACLE trial and any updates on efficacy/safety [news · 2026-09-01].
- Cash burn rate and any additional financing rounds given limited runway [news · 2026-09-01].
- Commercial launch preparations, including the appointment of a Chief Commercial Officer [news · 2026-09-08].
Sources: News · Pipeline · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run PMV Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PMV Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 5.1%
- Days to cover
- 6.5
- Shares short
- 2,633,561
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMVP short interestGovernance
Frequently asked questions
What is the AI investment thesis for PMV Pharmaceuticals, Inc.?
PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53, with its lead candidate rezatapopt in Phase 2 for p53 Y220C-mutant solid tumors and an NDA submission planned for Q1 2027 [sec_mda · as of 2026-08-14].
Who is the CEO of PMV Pharmaceuticals, Inc.?
Dr. David H. Mack Ph.D. is the chief executive officer of PMV Pharmaceuticals, Inc. (PMVP).
Where is PMV Pharmaceuticals, Inc. headquartered?
PMV Pharmaceuticals, Inc. (PMVP) is headquartered in Princeton, NJ, United States.
What therapeutic areas does PMV Pharmaceuticals, Inc. focus on?
PMV Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.